Metabolic reprogramming is a hallmark of cancer. Herein we discover that the key glycolytic enzyme pyruvate kinase M2 isoform (PKM2), but not the related isoform PKM1, is methylated by co-activator-associated arginine methyltransferase 1 (CARM1). PKM2 methylation reversibly shifts the balance of metabolism from oxidative phosphorylation to aerobic glycolysis in breast cancer cells. Oxidative phosphorylation depends on mitochondrial calcium concentration, which becomes critical for cancer cell survival when PKM2 methylation is blocked. By interacting with and suppressing the expression of inositol-1,4,5-trisphosphate receptors (InsP 3 Rs), methylated PKM2 inhibits the influx of calcium from the endoplasmic reticulum to mitochondria. Inhibiting PKM2 methylation with a competitive peptide delivered by nanoparticles perturbs the metabolic energy balance in cancer cells, leading to a decrease in cell proliferation, migration and metastasis. Collectively, the CARM1-PKM2 axis serves as a metabolic reprogramming mechanism in tumorigenesis, and inhibiting PKM2 methylation generates metabolic vulnerability to InsP 3 R-dependent mitochondrial functions.
reverses aerobic glycolysis to oxidative phosphorylation and reduces tumour formation in nude mice 14 , identifying PKM2 as a potential cancer therapy target. However, a recent report challenged the PKM2catalysed reaction as a rate-limiting step in cancer cell glycolysis 15 and a possible protein kinase activity of PKM2 remains controversial 16 .
Co-activator-associated arginine methyltransferase 1 (CARM1), also known as PRMT4, is a type I protein arginine methyltransferase (PRMT) that asymmetrically dimethylates protein substrates including histones, transcriptional factors and co-regulators, splicing factors and RNA polymerase II [17] [18] [19] [20] . CARM1 is overexpressed in breast cancer to promote cancer growth 21 , and elevated CARM1 expression correlates with poor prognosis 22 . Recently, we discovered that chromatin remodelling factor BAF155 methylation by CARM1 promotes breast cancer progression and metastasis 23 . However, whether CARM1 regulates energy metabolism in cancer cells remains unknown.
Here, we discovered CARM1-PKM2 interaction as a major contributor to metabolic reprogramming in cancer. CARM1 methylates the dimeric form of PKM2 at Arg445/447/455. Methylated PKM2 promotes tumour cell proliferation, migration and lung metastasis by reprogramming oxidative phosphorylation to aerobic glycolysis, and this effect was reversed by a competitive PKM2 peptide delivered using nanoparticles. We showed that methylated PKM2 localized in mitochondria-associated endoplasmic reticulum membrane, through interaction with inositol 1,4,5-trisphosphate receptors (InsP 3 Rs), decreasing mitochondrial membrane potential ( Ψ m ) and Ca 2+ uptake, which is essential for activating pyruvate dehydrogenase (PDH) to support oxidative phosphorylation 24 . Blocking PKM2 methylation elevates InsP 3 R expression, increasing mitochondrial Ca 2+ uptake, PDH activation and oxidative phosphorylation. Thus, PKM2 methylation represents an important regulator of switching between oxidative phosphorylation to aerobic glycolysis in cancer cells.
RESULTS

CARM1 interacts with and methylates PKM2
Consistent with CARM1 promotion of tumour development and progression 21, 23 , knocking out CARM1 decreased DNA synthesis in MCF7 cells ( Supplementary Fig. 1a ). CARM1 knockout (KO) also increased mitochondrial oxygen consumption rate (OCR) but decreased lactate production without affecting glucose uptake ( Supplementary Fig. 1b-f ). These results prompted us to test whether CARM1 modulates energy metabolism in breast cancer cells. We identified PKM2 as a putative CARM1-interacting protein by mass spectrometry when Halo-tagged CARM1 was overexpressed in HEK293T cells ( Supplementary Table 1 ). Endogenous CARM1-PKM2 interaction was confirmed by reciprocal co-immunoprecipitation in MCF7 cells (Fig. 1a ). To determine whether CARM1 directly interacts with PKM2, we performed glutathione S-transferase (GST) pulldown using recombinant GST-tagged CARM1, Flag-tagged PKM2 and Flag-PABP1 (positive control) 25 and observed that GST-CARM1, but not GST alone, bound PKM2, indicating direct CARM1-PKM2 interaction ( Fig. 1b) . Interestingly, recombinant PKM1 also associated with CARM1 in vitro ( Fig. 1b) . To map the PKM2 region that binds CARM1, we expressed truncated Flag-PKM2 using in vitro transcription and translation and performed in vitro interaction assays with GST-CARM1. Deleting PKM2 domain C ( 1) or N/A1 ( 4) significantly decreased the interaction of PKM2 with CARM1, and truncation of both domains ( 8) completely abolished the interaction, suggesting that the C and N/A1 domains are responsible for the interaction (Fig. 1c,d ). Although these domains are identical between PKM1 and PKM2, intriguingly only PKM2, but not PKM1, can be methylated by CARM1 in vitro (Fig. 1e ).
Since non-methylatable PKM1 forms only tetramers while methylatable PKM2 forms tetramers or dimers, we hypothesized that tetramer formation may prevent CARM1-mediated methylation. TEPP-46 (ref. 26 ), a PKM2 activator, or FBP stimulated PKM2 tetramer formation ( Supplementary Fig. 2a,b ), inhibiting PKM2 methylation by CARM1 ( Fig. 1f ). Neither TEPP-46 nor FBP affected histone H3 methylation by CARM1 ( Fig. 1f ), excluding the possibility that TEPP-46 and FBP interfere with CARM1 methyltransferase activity. Thus, only the dimeric form of PKM2 is methylated by CARM1.
Mammalian genomes encode nine PRMTs that sometimes share the same substrates 17 . Using purified Halo-tagged 23 PRMTs (1-8), we assayed methylation of recombinant PKM2 by PRMTs and showed that PKM2 is uniquely methylated by CARM1 ( Fig. 1g ).
CARM1 methylates PKM2 at Arg445/447/455
To narrow down the PKM2 methylation site(s), we assayed methylation in vitro using purified GST-tagged full-length (FL) or truncated PKM2 ( Fig. 2a ). Among the three truncated fragments, only the C domain was significantly methylated (Fig. 2b ), suggesting that it might contain the methylation site(s) of PKM2. Three arginine residues (Arg445, Arg447 and Arg455) were identified in the in vitro methylated GST-PKM2 (390-531 amino acid) fragment using liquid chromatography coupled tandem mass spectrometry (LC-MS/MS) ( Fig. 2c) . To further discern the major methylation site(s) of PKM2, we substituted lysine for the three methylated arginines to preserve their positive charge, individually or in combination, in GST-PKM2 ( Fig. 2d ). While individually mutating each arginine site slightly affected PKM2 methylation ( Fig. 2e ), mutating any two sites dramatically decreased methylation, and mutating all three sites abolished methylation ( Fig. 2e ). While all three arginine residues reside in the C domain that fosters tetramer formation, none is at the tetrameric interface ( Supplementary Fig. 2a ). Sizeexclusion chromatography using purified recombinant His-tagged proteins showed that neither PKM2 ( Supplementary Fig. 2b ) nor PKM1 ( Supplementary Fig. 2c ) tetramer formation was affected by mutating Arg445, Arg447 and Arg455 to lysine. Thus, while CARM1 predominantly methylates dimeric PKM2, PKM2 tetramer formation is not affected by PKM2 methylation. PKM1 is not methylated by CARM1 possibly because the corresponding arginines in tetrameric PKM1 are inaccessible to CARM1.
Inhibiting PKM2 methylation decreases breast cancer cell proliferation and migration and tumour growth
To investigate the function of PKM2 methylation in breast cancer cell lines, we employed CRISPR/Cas9 technology to knock out endogenous PKM2. Genomic DNA sequencing of two representative PKM2-KO clones of MCF7 or MDA-MB-231 revealed non-homologous endjoining-induced random insertions or deletions at the targeted site ( Supplementary Fig. 3a ), causing mRNA degradation and PKM2 protein loss (Fig. 3a,b ). Specific PKM2 KO led to compensatory PKM1 induction ( Fig. 3a,b ), as in primary mouse embryonic fibroblast (MEF) cells 27 . Whole-proteome analysis showed that, among >4,000 proteins detected, 158 proteins significantly increased (fold >= 1.5, P < 0.05), and 261 proteins decreased (fold <= 0.7, P < 0.05) in PKM2 KO versus parental cells ( Fig. 3c and Supplementary Table 2 ). In agreement with specific PKM2 KO, PKM2 protein levels decreased by >5-fold and PKM1 increased by >1.6-fold. The total PK activity in PKM2-KO cells decreased as compared with the parental cells (Supplementary Fig. 3b ), possibly because PKM1 restoration in PKM2-KO cells is insufficient to compensate PKM2 loss. No PK activity change was observed in paired parental and CARM1-KO MCF7 and MDA-MB-231 cell lines ( Supplementary Fig. 3c ), indicating that CARM1mediated PKM2 methylation does not affect PKM2 PK activity.
In MEF cells, deleting PKM2 from one or both allele(s) stimulated PKM1 expression and arrested proliferation, with reduced DNA synthesis due to PKM1 expression, rather than PKM2 loss 27 . Similarly, EdU incorporation and S-phase accumulation revealed dramatically reduced DNA synthesis when PKM2 was knocked out in MCF7 cells ( Fig. 3d,e ). However, the mechanism of reduced DNA synthesis in MCF7 cells appears to differ from that of MEF cells. PKM2 KO 
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In vitro interaction induced massive reduction of nucleotides in MEF cells 27 , but not in MCF7 and MDA-MB-231 cells ( Supplementary Table 3 ). Thus, reduced DNA synthesis in MCF7 cells was not due to lack of nucleotides, as in MEFs. Also in contrast to MEFs 27 , PKM1 overexpression in MCF7 cells did not inhibit cell proliferation ( Supplementary Fig. 3d ) in the presence of PKM2 expression. To delineate the functions of PKM2 methylation on energy metabolism without interference from PKM1, we restored PKM2 WT or PKM2 mut (where mut = mut1,2,3 from Fig. 2d ) in PKM2-KO cell lines, followed by knocking down PKM1 ( Fig. 3f ). While knocking down PKM1 60-80% in PKM2-KO cells did not affect cell proliferation and oxidative phosphorylation (Supplementary Fig. 3e -g), cell viability was dramatically reduced when PKM1 knockdown (KD) reached nearly 100%, possibly because these cells have insufficient PK to support survival. To ensure that PKM2 mut was defective in PKM2 methylation, we generated an antibody against an asymmetrically dimethylated Arg445 and Arg447 peptide of PKM2, referred to as the methyl-PKM2 antibody. While PKM2 WT and PKM2 mut were restored to similar levels, methylated PKM2 was detected only in parental and PKM2 WT -expressing cells, but not in PKM2-KO or PKM2 mut -expressing cells ( Fig. 3f ) or in CARM1-KO cells ( Supplementary Fig. 3h ), demonstrating the antibody specificity. We used these cell lines to investigate the effects of methyl-PKM2 on cell proliferation and colony formation in MCF7 cells and cell migration in MDA-MB-231. PKM2 methylation-defective cells (for example, PKM2 KO and PKM2 mut ) elicited reduced cell proliferation and colony formation ( Fig. 3g and Supplementary Fig. 3i ) compared with parental and PKM2 WT MCF7 cells; however, these effects appeared not to be caused by apoptosis ( Supplementary Fig. 3j ). PKM2 methylation status also affected cell migration ( Fig. 3h ) and tumour growth of MDA-MB-231 xenografts (Fig. 3i,j) . Therefore, PKM2 methylation is required for promoting cell proliferation, migration and tumour growth in various breast cancer cell models. (j) Representative images of the xenograft tumours. Statistical significance was assessed using ANOVA. In a,d,g,i, data are shown as mean ± s.d. and statistics source data are available in Supplementary Table 7 . Statistical significance was assessed using two-tailed t-test (a,d) and ANOVA (g,i), * * * P < 0.001. In b,f,h, data represent one of three independent experiments with similar results. Unprocessed original scans of blots are shown in Supplementary Fig. 9 .
Blocking PKM2 methylation results in elevated mitochondrial respiration in breast cancer cells We next examined whether PKM2 methylation regulates metabolic fluxes. The switch from PKM2 to PKM1 in MCF7 and MDA-MB-231 PKM2-KO cells significantly increased OCR and reduced lactate production ( Fig. 4a-c) . Remarkably, the balance of OCR and lactate production could be reversed by restoring PKM2 WT , but not PKM2 mut (Fig. 4b,c In a-c,e-g, data are shown as mean ± s.d. and statistics source data are available in Supplementary Table 7 . Statistical significance was assessed using two-tailed t-test (f,g) and ANOVA (b,c), * * P < 0.01, * * * P < 0.001. In d, data represent one of three independent experiments with similar results. Unprocessed original scans of blots are shown in Supplementary  Fig. 9 .
( Fig. 4e-g) . Thus, PKM2 methylation modulates energy metabolism in cancer cells. Reactive oxygen species (ROS), an inevitable by-product of mitochondrial oxidative phosphorylation, are often scavenged by nicotinamide adenine dinucleotide phosphate (NADPH) and glutathione (GSH) 1, 28 . As blocking PKM2 methylation increases oxidative phosphorylation, it may elevate ROS and deplete NADPH and GSH. Indeed, ROS levels were elevated by knocking out PKM2 (Supplementary Fig. 4a ), mutating PKM2 methylation sites (Supplementary Fig. 4b ) or knocking out CARM1 ( Supplementary Fig. 4c ) in MCF7 cells relative to corresponding controls, and increased ROS was accompanied by a decreased NADPH/NADP + ratio ( Supplementary  Fig. 4d ,e) and GSH concentration ( Supplementary Fig. 4f,g) . Similarly, the NADPH/NADP + ratio ( Supplementary Fig. 4h ) and GSH concentration ( Supplementary Fig. 4i ) were higher in parental and PKM2 WT -expressing cells than PKM2-KO and PKM2 mut -expressing MDA-MB-231 cells. However, mitoTEMPO, a specific scavenger of mitochondrial superoxide, and glutathione did not alter cell proliferation and migration in cells producing high levels of ROS (that is, PKM2-KO expressing PKM2 mut and CARM1-KO cells) ( Supplementary Fig. 4j-o) . Thus, glycolytic metabolism and growth effects regulated by PKM2 methylation are largely independent of ROS.
Inhibiting PKM2 methylation increases Ca 2+ uptake and mitochondrial membrane potential To investigate the mechanism by which mitochondrial respiration was elevated in PKM2 methylation-defective cells relative to PKM2 methylation-competent cells, we evaluated the effects of PKM2 methylation on mitochondrial membrane potential ( Ψ m ), an indicator of oxidative energy metabolism. Incorporation of mitochondrial-specific JC-1 dye followed by flow cytometry showed that Ψ m increased after knocking out PKM2 in MCF7 cells, and that restoring PKM2 WT , but not PKM2 mut , in PKM2-KO cells abrogated increased Ψ m (Fig. 5a ). To validate this, we used tetramethylrhodamine ethyl ester (TMRE) to measure Ψ m . Similar results were obtained in both MCF7 ( Fig. 5b ) and MDA-MB-231 cells ( Supplementary Fig. 5a ). In accordance with the PKM2 methylationdependent Ψ m change, CARM1 KO also increased Ψ m in MCF7 cells ( Fig. 5c ). Increased mitochondrial DNA copy number is another indicator of increased mitochondrial activity. Ablating PKM2 expression or PKM2 methylation resulted in increased mitochondrial DNA content in MCF7 cells ( Supplementary Fig. 5b ). Therefore, PKM2 methylation suppresses mitochondrial function and loss of PKM2 methylation releases this suppression and elevates Ψ m .
Mitochondrial Ca 2+ , primarily driven by Ψ m , stimulates oxidative phosphorylation to maintain cellular energy homeostasis 24, 29 . Ψ m sensitivity to PKM2 methylation prompted us to assess basal mitochondrial Ca 2+ concentration ([Ca 2+ ] mito ) using a Ca 2+ -sensitive Rhod-2 AM dye and confocal imaging ( Fig. 5d ). PKM2 KO profoundly increased basal [Ca 2+ ] mito in MCF7 ( Fig. 5e ,f) and MDA-MB-231 ( Fig. 5g ) cells. The effect is not cancer-cell-specific, as [Ca 2+ ] mito also increased in PKM2-KO MEF cells (PKM2 fl/fl , Cre-oestrogen receptor) 27 (Fig. 5h ). Restoring PKM2 WT , but not PKM2 mut , abrogated the elevated basal [Ca 2+ ] mito caused by PKM2 KO in MCF7 and MDA-MB-231 cells ( Fig. 5f ,g). Basal [Ca 2+ ] mito was also elevated in CARM1-KO MCF7 cells ( Fig. 5i ). Thus, methylated PKM2 suppresses mitochondrial Ca 2+ uptake. Mitochondrial matrix calcium regulates oxidative phosphorylation through activating several dehydrogenases, including PDH, which couples glycolysis to the tricarboxylic acid (TCA) cycle by pyruvate decarboxylation 24 . PDH activity is suppressed by phosphorylation by PDH kinase and enhanced by dephosphorylation by Ca 2+ -dependent pyruvate phosphatases 24, 30 . To investigate whether altered [Ca 2+ ] mito levels change PDH activity, we measured phosphorylated PDH levels in PKM2-KO, CARM1-KO and PKM2 WT -or PKM2 mut -restored cell lines by western blot. PKM2 KO dramatically decreased PDH phosphorylation in MCF7 ( Fig. 5j ), MDA-MB-231 ( Fig. 5k ) and MEF ( Fig. 5l ) cells, implying increased PDH activity by [Ca 2+ ] mito influx. Restoring PKM2 WT , but not PKM2 mut , increased phosphorylated PDH in MCF7 and MDA-MB-231 cells ( Fig. 5j ,k), implying attenuated PDH activity. CARM1 KO similarly decreased PDH phosphorylation in MCF7 ( Fig. 5m ). As expected, treating cells with dichloroacetate (DCA), a PDH kinase inhibitor, also decreased PDH phosphorylation and lactate production while increasing oxidative phosphorylation ( Fig. 5n-q) . Thus, PKM2 methylation is critical for restraining mitochondrial oxidative phosphorylation via decreasing mitochondrial Ψ m and Ca 2+ uptake, and increasing PDH phosphorylation.
Methylated PKM2 decreases InsP 3 R expression
A previous study reported PKM2 in mitochondria 31 . We confirmed PKM2 in the mitochondrial fraction by subcellular fractionation ( Supplementary Fig. 6a ) and observed a portion of PKM2 co-localizing with HSPA9 in mitochondrial outer membrane ( Supplementary Fig. 6b ). However, the mitochondrial localization of PKM2 appeared not to be affected by its methylation ( Supplementary  Fig. 6c ). To elucidate how methylated PKM2 modulates mitochondrial oxidative phosphorylation, we overexpressed Flag-tagged PKM2 WT or PKM2 mut in HEK293T cells, and performed MS analyses on Flag-PKM2 co-immunoprecipitated proteins to identify differentially interacting proteins. Many interacting proteins were identical between PKM2 WT and PKM2 mut ( Supplementary Tables 4 and 5) ; however, the endoplasmic reticulum (ER) calcium-releasing proteins InsP 3 R1, 2 and 3 showed the most notable difference between PKM2 WT and PKM2 mut ( Supplementary Fig. 6d ). Interestingly, InsP 3 R1 and InsP 3 R3 are not only putative PKM2-interacting proteins but their levels also increased in PKM2-KO MCF7 cells ( Fig. 3c and Supplementary  Fig. 6e ). To confirm the proteomics results, we examined InsP 3 R1 and InsP 3 R3 expression levels by western blotting in different PKM2-KO clones from MCF7 and MDA-MB-231 cells. Both InsP 3 R1 and InsP 3 R3 were significantly elevated in three different PKM2-KO clones of two cell lines ( Fig. 6a ). As a negative control, levels of HSPA9, another PKM2-interacting protein, were insensitive to PKM2 KO. To test whether increased InsP 3 Rs resulted from increased PKM1 in PKM2-KO cells, we measured the kinetics of protein changes in immortalized, tamoxifen-inducible PKM2-KO (PKM2 fl/fl , Creoestrogen receptor) MEFs. As reported previously 27 , PKM1 expression was elevated after a two-day 4-hydroxytamoxifen (4-OHT) treatment and plateaued after four-day treatment ( Fig. 6b ). However, increased InsP 3 R1 and InsP 3 R3 levels were detected only later when PKM2 was substantially lower (Fig. 6b ). Moreover, overexpressing PKM1 failed to increase InsP 3 R expression ( Supplementary Fig. 6f ), reinforcing that InsP 3 Rs are regulated by PKM2 not PKM1. Co-immunoprecipitation showed that PKM2, but not PKM1, interacted with the endogenous InsP 3 R1 and InsP 3 R3 in breast cancer cells ( Fig. 6c and Supplementary  Fig. 6g ). Thus, elevated InsP 3 R levels in PKM2-KO cells probably result from PKM2 loss rather than PKM1 gain. Inverse expression changes of InsP 3 Rs and PKM2 were also observed in The Cancer Genome Atlas (TCGA) breast tumour specimens 32 . Across 1,093 primary breast tumours in TCGA, CARM1 and PKM2 mRNA levels were positively correlated but negatively correlated with InsP 3 R1 and InsP 3 R2 expression ( Fig. 6d) . Similarly, in the CPTAC 77 breast tumour proteogenomics database 33 , InsP 3 R2 protein level was negatively correlated with CARM1 or PKM (Fig. 6e ).
To determine whether PKM2-InsP 3 R interaction is affected by PKM2 methylation, we precipitated PKM2 from MCF7 cells Supplementary Table 7 .
Statistical significance was assessed using two-tailed t-test (h,p,q) and ANOVA (b,c,f,g,i), * P < 0.05, * * P < 0.01, * * * P < 0.001. NS, not significant. In d,e, data represent one of two independent experiments with similar results. In a,j-o, data represent one of three independent experiments with similar results. Unprocessed original scans of blots are shown in Supplementary  Fig. 9 .
stably expressing Flag-tagged PKM2 WT or PKM2 mut using anti-Flag M2 resin. PKM2-InsP 3 R interaction was detected in PKM2 WTbut not PKM2 mut -expressing cells (Fig. 6f, upper panel) . Even when Flag-PKM1 was overexpressed in HEK293T PKM2-KO cells, no PKM1-InsP 3 R interaction was detected ( Fig. 6f , lower panel). Interestingly, InsP 3 R expression appears sensitive to PKM2 methylation since restoring PKM2 WT , but not PKM2 mut , abrogated elevated InsP 3 R expression in PKM2-KO cells (Fig. 6g ). Furthermore, Supplementary  Fig. 9 .
blocking PKM2 methylation by knocking out CARM1 or TEPP-46 treatment elevated InsP 3 R3 expression ( Supplementary Fig. 6h ). Thus, InsP 3 R expression is inversely correlated with methylated PKM2. ChIP-seq 34 revealed p53 binding to InsP 3 R promoters, indicating that InsP 3 Rs could be direct p53 target genes. InsP 3 R mRNA levels were increased by PKM2 KO, particularly in MDA-MB-231 cells ( Supplementary Fig. 6i ), consistent with increased p53 protein levels in PKM2-KO clones of MCF7, MDA-MB-231 and MEF cells (Fig. 6a,b ). Knocking down p53 using short hairpin RNAs (shRNAs) significantly decreased InsP 3 R protein levels (Fig. 6h ). p53 protein levels were sensitive to PKM2 methylation, as restoring PKM2 WT but not PKM2 mut reduced p53 expression ( Fig. 6g ). Conversely, CARM1 KO induced p53 expression ( Fig. 6i ). Accordingly, methylated PKM2, via downregulating p53, is one means to control InsP 3 R levels.
Methylated PKM2 restrains mitochondrial addiction to Ca 2+ through InsP 3 Rs
To test whether methylated PKM2 regulates mitochondrial functions through modulating InsP 3 Rs, which sustain mitochondrial functions, we stably knocked down InsP 3 R3 in MCF7 PKM2-KO and MDA-MB-231 cell lines, which highly express InsP 3 R3 (Supplementary Fig. 7a,b ). InsP 3 R3 KD reduced the basal [Ca 2+ ] mito level (Fig. 7a,b ) and Ψ m ( Fig. 7c and Supplementary Fig. 7c ). Similarly, OCR was decreased by knocking down InsP 3 R3 in MCF7 PKM2-KO ( Fig. 7d ) and MDA-MB-231 cells (Fig. 7e) . To delineate the roles of InsP 3 Rs in PKM2-modulated mitochondrial activity, we knocked down InsP 3 R3 in PKM2 WT -or PKM2 mut -expressing cells. InsP 3 R3 KD significantly reduced OCR in PKM2 WT or PKM2 mut cells. Basal OCR in PKM2 mut /shInsP 3 R3 cells was higher than in (i,j) Cell death measured by PI staining in parental MCF7, PKM2-KO, PKM2 WT /shPKM1 and PKM2 mut /shPKM1 cells after treatment with 3.5 µM XeB for 24 h (i) or in parental MDA-MB-231, PKM2-KO, PKM2 WT /shPKM1 and PKM2 mut /shPKM1 cells after treatment with 5 µM XeB for 24 h (n = 3 independent experiments). In a,b,d-g,i,j, data are shown as mean ± s.d. and statistics source data are available in Supplementary Table 7 . Statistical significance was assessed using two-tailed t-test (a,b,d,e) and ANOVA (f,g,i,j), * P < 0.05, * * P < 0.01, * * * P < 0.001. In f (lower panel) and g (lower panel), data represent one of three independent experiments with similar results. Unprocessed original scans of blots are shown in Supplementary  Fig. 9 .
PKM2 WT /shInsP 3 R3 cells, possibly due to other InsP 3 Rs (InsP 3 R1 and 2) that remain abundant in PKM2 mut cells (Fig. 7f,g) . Calcium transport between the ER and mitochondria is essential for Ca 2+ homeostasis and cell survival 29 . To assess the importance of calcium haemostasis and oxidative phosphorylation to cell survival in PKM2-KO or methylation-defective cells, we treated cells with xestospongin B (XeB), a specific InsP 3 R inhibitor, to inhibit IP3R-mediated ER Ca 2+ release. PKM2-KO or PKM2 mut cells were more vulnerable to XeB than parental and PKM2 WT cells (Fig. 7h-j and Supplementary  Fig. 7d ), indicating that addiction to oxidative phosphorylation following loss of PKM2 methylation plays essential roles in cell survival. Thus, methylated PKM2 repressed mitochondrial addiction to Ca 2+ via interacting with and suppressing the expression of InsP 3 Rs.
Inhibiting PKM2 methylation with a nanoparticle-delivered competitive peptide blocks cancer cell metastasis in vivo
Having established that PKM2 methylation controls ERmitochondrial Ca 2+ signalling and promotes breast cancer cell proliferation and migration, we investigated whether PKM2 methylation can be therapeutically targeted. To assess PKM2 methylation dynamics, we estimated the extent of endogenous PKM2 methylation in cancer cells. We used excess methyl-PKM2 antibody for immunoprecipitation and measured the proportion of PKM2 in the supernatant and pellets (that is, in the methylated form) in MCF7 cells. Approximately 40% of endogenous PKM2 was methylated ( Supplementary Fig. 8a ). This partial PKM2 methylation in cancer cells implies that PKM2 methylation is dynamic and regulatable. Peptide drugs have made huge impacts on cancer treatment 35 . We evaluated whether a competitive, non-methylated PKM2 peptide encompassing the methylation sites could inhibit endogenous PKM2 methylation and reverse aerobic glycolysis to oxidative phosphorylation. As a negative control, we also synthesized a corresponding peptide with Arg445 and Arg447 asymmetrically dimethylated. In vitro, the non-methyl-peptide, but not the control methyl-peptide, abrogated CARM1-mediated methylation of PKM2 (Fig. 8a) . In contrast, the peptides only partially inhibited methylation of histone H3, a control CARM1 substrate, suggesting that PKM2 is the primary target of inhibition by this peptide. We employed unimolecular nanoparticles (UMNPs) to deliver a peptide to inhibit methylation of PKM2 in vivo ( Supplementary  Fig. 8b-f ). To ensure that UMNP encapsulation did not alter the PKM2 peptide's inhibitory activity, we performed PKM2 in vitro methylation assay in the presence of non-methyl-peptide-loaded UMNP or methyl-peptide-loaded UMNP. The UMNP-non-methylpeptide, but not UMNP-methyl-peptide, inhibited CARM1-mediated PKM2 methylation (Fig. 8b ). Under this condition, histone H3 methylation was not inhibited. The results imply that UMNP-nonmethyl-peptide selectively inhibited PKM2 methylation, an effect similar to expressing PKM2 mut and TEPP-46 treatment. MDA-MB-231 cells efficiently took up the 6-carboxyfluorescein-conjugated peptide (FAM-peptide)-loaded UMNPs in a dose-dependent manner (Fig. 8c ). In addition, only UMNP-non-methyl-peptide inhibited endogenous PKM2 methylation, increasing InsP 3 R3 protein levels (Fig. 8d ). Treatment with UMNP-non-methyl-peptide significantly increased OCR in MCF7 and MDA-MB-231 cells relative to the UMNP-methyl-peptide control (Fig. 8e,f) . Just as CARM1 KO did not affect PK activity ( Supplementary Fig. 3c ), inhibiting PKM2 methylation by UMNP-non-methyl-peptide did not alter PKM2 PK activity ( Supplementary Fig. 8g ). Moreover, the non-methyl-peptide, but not methyl-peptide, inhibited MCF7 cell proliferation ( Fig. 8g ) and MDA-MB-231 cell migration (Fig. 8h ). To test whether the competitive PKM2 peptide inhibits breast cancer lung metastasis in vivo, LM2 cells 36 , a metastatic MDA-MB-231 derivative clone, were tail-vein-injected into nude mice. While the majority of cells did not survive one day after injection, the remaining cells colonized in the lungs and reached 30-40% of the initial cell numbers by day 7. The mice were treated with UMNPs loaded with methyl-peptide or nonmethyl-peptide on day 8 and treatment continued for three weeks. LM2 colonization and outgrowth in the lungs of the two cohorts were monitored by bioluminescence imaging 23 . Bioluminescence intensities in the UMNP-non-methyl-peptide-treated group were significantly decreased compared with those in the UMNP-methylpeptide-treated group, indicating that non-methyl-peptide inhibited LM2 lung colonization (Fig. 8i,j) . Thus, targeting PKM2 methylation is a feasible therapeutic strategy to reverse oncogenic processes.
DISCUSSION
We show here that reversible PKM2 methylation reprogrammes cancer metabolism from oxidative phosphorylation to aerobic glycolysis. PKM2 methylation by CARM1 inhibits Ca 2+ influx from ER to mitochondria. In breast cancer cells, mitochondrial oxidative phosphorylation dramatically increased following the loss of CARM1, PKM2 or PKM2 methylation, increasing basal mitochondrial [Ca 2+ ] and Ψ m ( Supplementary Fig. 8h ). These findings provide mechanistic insights into the metabolic reprogramming controlled by the CARM1-PKM2 axis in breast cancer cells and show that inhibiting PKM2 methylation has therapeutic applications.
PKM2 plays an important role in aerobic glycolysis by distributing glycolytic intermediates for anabolic and catabolic purposes in cancer cells 11 . Several post-translational modifications of PKM2 (refs 37,38) have been reported to modulate PKM2 function by inhibiting PK activity. However, a recent study challenged the PKM2-catalysed reaction as a rate-limiting step in cancer cell glycolysis 15 . Consistent with this, PKM2 PK activity was not affected by knocking out CARM1 ( Supplementary Fig. 3c ), or by inhibiting PKM2 methylation using non-methyl-PKM2 peptide ( Supplementary Fig. 8g ), suggesting that PKM2 methylation has little effect on its PK activity. Mitochondrial oxidative phosphorylation dramatically increased in CARM1-KO, PKM2-KO or PKM2 mut -expressing breast cancer cells, suggesting that non-glycolytic function of PKM2 regulates aerobic glycolysis rather than PK activity. Indeed, we found that PKM2 methylation elicits profound effects on energy production by altering mitochondrial oxidative phosphorylation. Notably, mitochondria have wellrecognized roles in producing ATP and intermediates for macromolecule biosynthesis in normal and cancerous cells, and are promising chemotherapeutic targets 8 . In breast cancer cells, knock down of mitochondrial p32, a critical regulator of tumour metabolism via maintenance of oxidative phosphorylation, shifted metabolism from oxidative phosphorylation to glycolysis, yet tumorigenesis was impaired 7 , suggesting that high levels of glycolysis without adequate oxidative phosphorylation do not always benefit tumour growth. Thus, our results support the notion that the balance between aerobic glycolysis and mitochondrial respiration is essential for tumour progression.
Cancer cells rely on mitochondria for TCA cycle intermediates to fuel lipid, nucleic acid and protein biosynthesis essential for growth 8 . The TCA cycle is regulated by mitochondrial Ca 2+ , which activates matrix dehydrogenases, including pyruvate-, α-ketoglutarate-and isocitrate-dehydrogenases 29 , to promote oxidative phosphorylation and ATP production 39 . Mitochondrial Ca 2+ is primarily taken from ER at mitochondria-associated ER membrane contacts. A minor fraction is from cytosol through low-affinity mitochondrial calcium uniporters. Both processes are tightly controlled by InsP 3 Rs, the ubiquitous family of ER Ca 2+ -release channels 40 . Interestingly, we found that InsP 3 R expression levels are inversely associated with PKM2 expression, and are sensitive to PKM2 methylation, that is, high InsP 3 Rs in PKM2 methylation-defective cells. Accordingly, mitochondrial Ca 2+ uptake increases in PKM2 methylation-defective cells, activating PDH and increasing oxidative phosphorylation. PKM2 methylation, on the contrary, decreases InsP 3 R expression and [Ca 2+ ] mito , increasing PDH phosphorylation and inactivation, decreasing Ψ m , and switching energy homeostasis from mitochondrial respiration to aerobic glycolysis. We found that methylated PKM2 suppresses the expression of InsP 3 Rs via negatively regulating p53, the transcription factor regulating InsP 3 R expression. In addition to controlling InsP 3 R expression, methylated PKM2 co-precipitates with InsP 3 R1 and InsP 3 R3 (Fig. 6f) . Thus, methylated PKM2, through regulating InsP 3 R expression and interaction, delicately controls Ca 2+ uptake by mitochondria.
Mitochondrial Ca 2+ addiction was recently identified as a feature of cancer cells 41 . While inhibiting ER-to-mitochondria Ca 2+ transfer Supplementary Table 7 . Significance was assessed using two-tailed t-test (e,f,h) and ANOVA (g,i), * * P < 0.01, * * * P < 0.001. In a,b,d, data represent one of three independent experiments with similar results. Unprocessed original scans of blots are shown in Supplementary Fig. 9 .
creates a bioenergetic crisis in normal and tumour cells, normal cells trigger autophagy to sustain survival, whereas the same autophagic response in tumour cells is insufficient for survival. Tumour cell survival uniquely depends on InsP 3 R-regulated, constitutive ER-tomitochondria Ca 2+ transfer, since inhibiting InsP 3 R activity reduces cancer cell line proliferative potential in vitro and impairs tumour growth in vivo 41 . Accordingly, increased InsP 3 R expression and/or activity are associated with cancer cell proliferation, survival and invasiveness. All three InsP 3 R subtypes are expressed in breast cancer cells at various levels to regulate intracellular Ca 2+ release, which is essential for growth control of these cells 41 . Although inhibiting PKM2 methylation appears to reduce tumour cell growth, migration and metastasis in various breast cancer cell lines, it is insufficient to alter cell survival ( Supplementary Fig. 3j ), whereas inhibiting both PKM2 methylation and InsP 3 R activity is lethal to cancer cells (Fig. 7h-j) . The results indicate a gain of dependence on mitochondrial Ca 2+ by cancer cells in order to maintain cell viability. The acquired mitochondrial addiction to Ca 2+ renders cancer cells susceptible to therapies based on inhibiting InsP 3 R (for example, XeB). Thus, combinatory inhibition of InsP 3 R activity and PKM2 methylation may elicit synergistic therapeutic effects. Targeting cancer-specific metabolism pathways (that is, aerobic glycolysis and ER-to-mitochondria Ca 2+ transfer) should provide new therapeutic avenues for cancer treatment, as exemplified by the UMNP peptide delivery system here.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper.
Note: Supplementary Information is available in the online version of the paper METHODS Materials. The antibodies, reagents, shRNAs and primers are listed in Supplementary Table 6 .
Cell culture and generation of PKM2-knockout cells. MCF7, MDA-MB-231 and HEK293T cell lines were purchased from ATCC, LM2 was provided by J. Massagué (Howard Hughes Medical Institute), and immortalized MEFs (PKM2 fl/fl , Cre-ER) were kindly provided by M. G. Vander Heiden (Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology) and were maintained in DMEM supplemented with 10% fetal bovine serum (FBS) purchased from Gibco. None of the cell lines used in this study was found in the database of commonly misidentified cell lines that are maintained by ICLAC and NCBI Biosample. Cell lines were authenticated by short tandem repeat profiling and were routinely tested for mycoplasma contamination. PKM2-KO cell lines were generated using a PKM2specific CRISPR/Cas9/eGFP plasmid. For PKM2 KO in MEF cells, MEF cells were treated with 1 µM 4-hydroxytamoxifen (4-OHT) at least for 8-10 days to allow complete knockout of PKM2.
Virus packaging and stable cell line generation. For lentivirus packaging, three plasmids (PAX2-, VSVG-and pLKO-shRNA-expressing plasmid) were transfected into HEK293T cells. For retrovirus packaging, the three plasmids PHIT60-, VSVGand pLNCX-PKM2-expressing plasmid were employed. Supernatant containing the virus was harvested for cell line infection after 48 h. To generate stable cell lines expressing PKM2 wild type or methylation-defective mutant in accompanying with PKM1 KD, 2 × 10 5 PKM2-KO cells were seeded into six-well plates. For infection the next day, 1 ml of retrovirus was mixed with 1 ml fresh cell culture medium; Polybrene was added at a final concentration of 5 µg ml −1 to increase the infection efficiency.
On the second day, the cells were cultured with fresh medium containing 400 µg ml −1 G418 (or 200 µg ml −1 G418 for MDA-MB-231) for at least four weeks to obtain cell lines stably expressing the PKM2 wild type or the methylation-defective mutant To knock down PKM1, the above cell lines were infected with pLKO-PKM1 shRNA lentivirus and selected with 2 µg ml −1 puromycin for at least 2 weeks. The expression of PKM2 in stable cell lines was individually examined by western blotting.
Co-immunoprecipitation. Co-immunoprecipitation was performed as previously described 23 .
In vitro methylation assay. In vitro methylation assay was performed as previously described 23 .
Quantitative real-time PCR. Quantitative real-time PCR was performed as described previously 23 .
Gel filtration. Recombinant His-tagged PKM2 protein was incubated with TEPP-46 (10 µM) for 1 h on ice, and then separated in the Superdex 200 Increase 10/300 GL column (GE Healthcare) in 0.01 M phosphate buffer and 0.14 M NaCl at pH 7.4. The flow speed rate is 0.5 ml min −1 . Fractions (0.3 ml) were collected and analysed by UV absorbance or SDS-PAGE and western blot.
Pyruvate kinase and lactate dehydrogenase assays. Pyruvate activity was measured as described previously 42 . Briefly, 2 µg whole-cell lysate was incubated in 1 ml buffer (Tris pH 7.5 (50 mM), KCl (100 mM), MgCl 2 (5 mM), ADP (0.6 mM), phosphoenolpyruvate (0.5 mM), NADH (180 µM) and LDH (8 units)). The change in absorbance at 340 nm owing to the oxidation of NADH was measured using a Nanodrop ND-2000 1-position spectrophotometer (Thermo). LDH activity was determined by measuring the decreased fluorescence intensity at 340 nm from the NADH oxidation in buffer (Tris pH 7.5 (50 mM), KCl (100 mM), MgCl 2 (5 mM), pyruvate (20 mM), NADH (180 µM)).
Subcellular fractionation.
The isolation of cytosol and mitochondria was conducted as described previously 43 . Briefly, the cell pellets were resuspended in 11 ml ice-cold RSB hypo buffer (10 mM NaCl 1.5 mM MgCl 2 10 mM Tris-HCl (pH 7.5)) and the cells were allowed to swell for 5-10 min; then the swollen cells were broken open with several strokes in the presence of 8 ml of 2.5× MS homogenization buffer (525 mM mannitol, 175 mM sucrose, 12.5 mM Tris-HCl, 2.5 mM EDTA, pH 7.5) to give a final concentration of 1× MS homogenization buffer. The homogenate was centrifuged at 1,300g for 5 min, repeated several times. After centrifugation at 7,000g for 15 min, the supernatant (cytosolic fraction) and the crude mitochondria fraction were separated. The pellet was resuspended with 1× MS homogenization buffer followed by 7,000g sedimentation several times.
Confocal imaging. MAD-MB-231 cells were fixed with 4% paraformaldehyde in culture media for 15 min at 37 • C and permeabilized with 0.2% Triton X-100 for 10 min at room temperature. The nonspecific binding was blocked by incubation with 4% BSA in PBS for 60 min, and cells were subsequently stained with primary PKM2 and HSPA9 antibodies overnight at 4 • C. The slides were washed in PBS three times (5 min each time) and were incubated for 1 h with the following secondary antibodies: FITC-conjugated goat anti-mouse IgG and Dylight 594-conjugated goat anti-rabbit IgG. After being washed three times in PBS and air-dried, the coverslips were mounted in ProLong Gold anti-fade reagent with DAPI (Invitrogen). Fluorescence was examined using a Leica SP8 3X STED Super-resolution microscope equipped with a 63× objective lens with laser excitation at 405 nm, 488 nm or 592 nm. For z-stack analysis, optical sections were obtained along the z axis at 0.5-µm intervals. Images were analysed with ImageJ software.
Expression and purification of recombinant proteins. Human PRMT1-8 cDNAs were cloned into pFN21K HaloTag CMV Flexi Vector (Promega) and the corresponding proteins were purified as described previously 23 .
GST pulldown assays. GST and GST-CARM1 proteins were expressed in E. coli BL-21 competent cells and purified by glutathione Sepharose 4B resin (GE Healthcare Life Sciences). Recombinant, Flag-tagged PKM2 proteins were purified from HEK 293T cells. The GST pulldown experiment was conducted as described previously 23 .
In vitro protein-protein interaction assay. Flag-tagged full-length PKM2 and its truncation constructs were translated by the T7 Quick Coupled Translation/Transcription system (Promega). Interaction with GST-CARM1 fusion protein (1 µg ml −1 ) was conducted as described previously 23 .
Cell proliferation and DNA synthesis assays. The MTT assay was conducted as described previously 23 . For 5-ethynyl-2 -deoxyuridine (EdU) incorporation assay, 3 × 10 5 cells were seeded into a six-well plate and incubated with 10 µM EdU for 1 h, followed by procedures described in the Click-iT EdU cytometry assay kit on a BD LSRII. For the clonogenicity assay, 1,000 viable transfected cells were cultured in six-well plates for two weeks. Colonies were washed with PBS and fixed with 3.7% formaldehyde at room temperature for 15 min, and then stained for 20 min with 0.05% crystal violet.
Transwell cell migration assays. The Transwell cell migration assay was performed as described previously 23 . Briefly, 1 × 10 5 cells in 100 µl serum-free media were added into the upper chamber; 500 µl culture media with 20% FBS was in the lower well. After 12-h culture, cells on the upper surface of the membrane were removed and migrant cells on the lower surface were fixed with 3.7% formaldehyde in culture media at 37 • C for 15 min, and then stained with 0.05% crystal violet for 20 min.
Generation of methylated PKM2 (methyl-PKM2) specific antibody. Methyl-PKM2 specific anti-peptide antibody was generated by Genemed Synthesis. The KLHconjugated PKM2 peptide RYR(as)PR(as)APIIAVTC, with Arg445 and Arg447 asymmetrically dimethylated, was synthesized. This peptide corresponding to human PKM2 (amino acids 443-454) was used to immunize rabbits. Purification of antibody was conducted as described previously 23 .
Measurement of oxygen consumption rate. The OCR was measured in an XF96 extracellular analyser (Seahorse Bioscience). A total of 2 × 10 4 cells per well were seeded into a 96-well plate and incubated in DMEM media with 10% FBS at 37 • C. The next day, the medium was changed to analysis media containing 10 mM glucose. The cells were incubated in a CO 2 -free incubator at 37 • C for 1 h. Cells were sequentially exposed to oligomycin (1 µM), FCCP (1 µM) and rotenone (0.5 µM). Each point in the traces represents the average measurement from six different wells. Mass spectrometry analysis of arginine methylation. In-gel digestions. Experiments were performed with a previously described protocol with modifications 1 . Briefly, the gel was destained twice with 100 mM (NH 4 )HCO 3 /50% methanol, followed by dehydration with 25 mM (NH 4 )HCO 3 /50% acetonitrile and 100% acetonitrile. The gel particles were rehydrated with freshly prepared 25 mM dithiothreitol at 56 • C. The proteins were then alkylated with 55 mM iodoacetamide in the dark. The gel pieces were incubated with 50 ng of trypsin in 25 mM (NH 4 )HCO 3 /0.01% ProteasMAX (Promega) at 42 • C. The tryptic peptides were extracted by adding 2.5% TFA solution. Samples were analysed on a Waters nanoAcquity UPLC system coupled to a Q-Exactive quadrupole Orbitrap mass spectrometer (Thermo). Tryptic peptides DOI: 10.1038/ncb3630 were loaded onto the Waters Symmetry C18 trap column (180 µm × 20 mm, 5 µm) and separated over a 70 min gradient on the fabricated column (150 mm × 75 µm, 1.7 µm). The data were acquired under the data-dependent acquisition mode (DDA, top 20) . Mass spectrometric conditions were as follows: normalized high-energy collision dissociation (HCD) 30%, 70 K and 17.5 K resolution for full scan and MS/MS scan, automatic gain control (AGC) of 2×10 5 , maximum ion injection time of 100 ms, isolation window of 2 m/z, and fixed first mass of 100 m/z.
Mass spectral data were searched in PEAKS Studio (Bioinformatics) against a home-made FASTA database containing the PKM2 protein sequence. Trypsin was selected and two missed cleavage sites were allowed. PEAKS searches were performed with a precursor mass tolerance of 20 ppm and a fragment mass tolerance of 0.05 Da. The fixed modifications consisted of carbamidomethylation (57.0215 Da) of cysteine residues. The variable modifications consisted of dimethylation (28.0313 Da) of arginine residues and oxidation (15.9949 Da) of methionine. Peptide spectral matches were validated on the basis of P value of 1% false discovery rate.
Quantitative proteomics analysis. Cells were lysed in lysis buffer containing 8 M urea, 50 mM Tris-HCl, 30 mM NaCl, and a protease inhibitor tablet. The lysates were homogenized and processed by centrifugation. Protein content was determined by bicinchoninic acid (BCA) assay (Thermo). Protein extract was diluted to a urea concentration of 0.9 M and subjected to digestion with trypsin. The samples were quenched with 10% TFA and desalted with a Sep-Pak C18 cartridge (Waters).
DiLeu labelling was performed according to previous studies 2 . Briefly, each DiLeu tag was dissolved in anhydrous DMF and activated with DMTMM and NMM. The supernatant was used immediately to label the peptides and the reaction was quenched with hydroxylamine. Samples were pooled at a 1:1 ratio across all of the channels and dried in vacuo.
Strong cation exchange fractionation was performed on a Waters Alliance e2695 HPLC (Milford, MA) with a flow rate of 0.2 ml min −1 . Tryptic peptides were loaded onto a polySULFOETHYL A (200 mm × 2.1 mm, 5 µm) column. The samples were offline separated over a 90 min gradient, collected every 1.5 min and concatenated into 10 fractions.
All samples were reconstituted in 0.1% FA, 3% ACN and loaded onto the fabricated column (150 mm × 75 µm, 1.7 µm). Peptides were online separated with a Dionex UltiMate 3000 LC system before entering the Orbitrap Fusion Lumos tribrid mass spectrometer (Thermo). Survey scans (300-1,500 m/z) were acquired at a resolution of 60K, followed by top 15 HCD fragmentation (normalized collision energy 30, isolation window 1 m/z). Values of 2 × 10 5 and 5 × 10 5 were selected as the AGC target for MS and MS/MS scans, respectively. The maximum injection time was set to 100 ms.
The OMSSA Proteomic Analysis Software Suite (COMPASS) was used for peptide identification. Raw files were searched against the Homo sapiens Uniprot database (December 2015). Trypsin was selected as the enzyme and a maximum of two missed cleavages were allowed. Precursor and fragment ion tolerance were set to 25 ppm and 0.02 Da. DiLeu labelling on peptide N termini and lysine residues (+145.1267748 Da), and carbamidomethylation of cysteine residues (+57.02146 Da) were chosen as static modifications. Methionine oxidation (+15.99492 Da) and DiLeu labelling on tyrosine residues (+145.1267748) were selected as variable modifications. Search results were filtered to 1% false discovery rate at both the peptide and protein levels. Quantification was performed using an in-house software called the DiLeu tool. Reporter ion abundances are corrected for isotope impurities with python script.
Cellular metabolite extraction and analysis. Global metabolomic analysis of nucleotides was performed by Metabolon as described previously 44 .
Measurement of mitochondrial membrane potential ( Ψ ) and DNA content.
Cells were loaded with JC-1 (10 µg ml −1 ) for 10 min or tetramethylrhodamine ethyl ester (TMRE) for 20 min in phenol-red-free media at 37 • C followed by three washes with PBS. Trypsinized cells were subjected to flow cytometry analysis. Relative quantification of mitochondrial DNA levels was performed using the ratio of mitochondrial tRNA Leu to the nuclear-encoded B2-microglobulin 45 .
Measurement of calcium flux. Cells were loaded with Rhod-2 dye (MCF7 (1 µM), MDA-MB-231 and MEFs (0.45 µM)) and 0.002% Pluronic F-127 and incubated for 10 min at room temperature, and then the buffer was changed to Rhod-2-free buffer and the cells were incubated for a further 30 min. Calcium imaging was carried out by confocal microscopy at 561 nm excitation using a ×63 oil objective. Images were analysed and quantified using ImageJ (NIH).
Cell apoptosis and death analyses.
Cell apoptosis and death assays were conducted as described previously 41 . Cell apoptosis was determined by annexin V/APC and propidium iodide (PI) staining. Cell death was determined by PI staining using flow cytometry.
Unimolecular nanoparticle (UMNP) synthesis. β-benzyl L-aspartate N -carboxyanhydride (BLA-NCA) monomer, poly (β-benzyl L-aspartate)poly(ethylene glycol) (PBLA-PEG) block copolymers (that is, PBLA-mPEG and PBLA-PEG-Maleimide (Mal)), and poly(amidoamine)-poly(β-benzyl L-aspartate) -poly(ethylene glycol)-OCH 3 /Mal (PAMAM-PBLA-PEG-Mal) were all synthesized following the methods previously reported 46, 47 . 1 H NMR (400 MHz, CDCl 3 ). BLA-NCA: 7.42-7.28 (5H, m, Ar-H ), 6.30 (1H, s, NH ), 5.20 (2H, s, CH 2 -Ar), 4.6 (1H, t, CH ), and 2.9 (2H, t, COCHCH 2 ) ppm. 1 To synthesize PAMAM-PAsp(DET-Aco-r-Im)-PEG-TAT, PAMAM-PAsp(DET-Aco-r-Im)-PEG (20 mg), TAT (sequence CYGRKKRRQRRR, 0.3 mg) and tris(2carboxyethyl)phosphine hydrochloride (0.57 mg) were dissolved in PBS buffer (pH 7.4, 5 ml). After 24 h stirring, the solution was purified by dialysis against deionized water (MWCO 15 kDa). 1 To prepare PKM2 peptide-loaded UMNPs, 6-carboxyfluorescein (FAM)conjugated PKM2 peptide (FAM-PKM2 peptide, 0.5 mg) was dissolved in 0.5 ml deionized water under stirring, while the PAMAM-PAsp(DET-Aco-r-Im)-PEG-TAT polymer (UMNP, 2 mg) was dissolved in 1 ml deionized water at pH 7. The UMNP solution was slowly added to the peptide solution under stirring at room temperature for 4 h and dialysed against deionized water (MWCO = 100 kDa). The peptide loading level was determined by a UV-Vis spectrometer (Cary 5000 UV-Vis-NIR, Agilent Technologies) with the absorbance of FAM at 495 nm. UMNPnon-methyl-peptide and UMNP-methyl-peptide without FAM conjugation were prepared using the same method.
Characterization. The 1 H NMR spectra were collected on a Bruker Advance 400 NMR spectrometer. The hydrodynamic size distribution and zeta-potential of the UMNPs were characterized using a dynamic light scattering (DLS) spectrometer (Malvern Zetasizer Nano ZS) at a polymer concentration of 0.1 mg ml −1 .
Principle of PKM2 peptide delivery using UMNP. Positively charged PKM2 peptides were loaded onto the charge conversional polyanionic (PAsp(DET-Aco-r-Im)) segments through electrostatic interactions 49 . Under neutral pH (for example, the blood stream), the PAsp (DET-Aco-r-Im) segments carried negative charges, allowing for the complexation of the PKM2 peptides. Once the UMNPs were endocytosed by target cancer cells, the polyanionic PAsp(DET-Aco-r-Im) segments were converted to polycationic PAsp(DET-r-Im) segments in the acidic endocytic compartments due to the acid-induced cleavage of the aconitic acid side groups, thereby facilitating the release of PKM2 peptides. The imidazole functional groups were incorporated into the PAsp(DET-Aco-r-Im) segments to enhance the endosomal escape capability, thereby preventing potential damage of the peptides in the acidic endosomes/lysosomes 50 . A cell-penetrating peptide TAT was conjugated onto the surfaces of the nanocarriers to enhance their cellular uptake 51 .
Animal experiments. All animal work was performed in accordance with protocols approved by the Research Animal Resource Center of UW-Madison and the study was compliant with ethical regulations regarding animal research. Balb/c nude female mice at 4-6 weeks old were used for all xenograft experiments (Harlan). For xenograft tumours assays, 1 × 10 6 cells (MDA-MB-231 PKM2 WT /shPKM1 or PKM2 mut /shPKM1 cells) were injected into the inguinal mammary fat pads of nude mice (n = 6 per group). Tumour size was determined using calliper measurement and the tumour volume was calculated using the formula 1/2 × L × W 2 . For lung metastasis assays, 1 × 10 5 LM2, a metastatic MDA-MB-231 derivative clone, was resuspended in 0.1 ml PBS and tail-vein-injected into mice. Mice were imaged for luciferase activity immediately after injection (day 0) to exclude any mice that were not successfully xenografted. Luciferase-based non-invasive bioluminescent imaging and analysis were performed as described previously 36 using an IVIS Imaging System (Caliper Life Sciences). Briefly, mice were anaesthetized and injected intraperitoneally with 2 mg D-luciferin (20 mg ml −1 in PBS) (Gold Biotechnology). Imaging was completed between 5 to 15 min after injection. For bioluminescence plots, total photon flux was calculated for each mouse in the gated areas. Then, the mice were retro-orbitally injected with UMNP-methyl-peptide or UMNP-nonmethyl-peptide (100 µl, 1 g l −1 ) at the indicated time interval. Imaging was performed every week and endpoint assays were conducted four weeks after injection.
Statistics and reproducibility.
Statistical testing was performed using the unpaired two-tailed Student's t-test and/or ANOVA analysis. All experiments were repeated at least three times unless otherwise indicated. N numbers are indicated in the figure legends. P value < 0.05 ( * ) was considered as statistically significant.
Data availability. Mass spectrometry data have been deposited in ProteomeXchange with the primary accession code PXD007671 (http://www.ebi.ac.uk/pride/ archive) 52 . Global metabolomic nucleotide data have been deposited in MetaboLights with the primary accession code MTBLS533 (http://www.ebi.ac.uk/ metabolights/index) 53 . The RNA-seq data of 1,093 human primary solid breast tumour samples were derived from the TCGA Research Network: http:// cancergenome.nih.gov and they are available in FireBrowse (http://gdac. broadinstitute.org/runs/stddata__2016_01_28/data/BRCA/20160128/gdac. broadinstitute.org_BRCA.Merge_rnaseqv2__illuminahiseq_rnaseqv2__unc_edu_ _Level_3__RSEM_genes_normalized__data.Level_3.2016012800.0.0.tar.gz).
The proteomics data of 77 human breast tumour samples were derived from the CPTAC Research Network (https://proteomics.cancer.gov/programs/cptac) and they are available in (http://prot-shiny-vm.broadinstitute.org:3838/BC2016). Data related to CARM1-or PKM2-interacting proteins are provided in Supplementary Tables 1, 4 and 5. Source data for Figs 3a,d,g,i, 4a-c,e-g, 5b,c,f-h,p,q, 7a,b,d-g,i,j and 8e-i and Supplementary Figs 1a-f, 2b -d,f,g, 4a-l, 5a,b, 6i and 8g have been provided in Supplementary Table 7 . All other data supporting the findings of this study are available from the corresponding author on reasonable request.
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Experimental design 1. Sample size
Describe how sample size was determined.
No statistical method was used to predetermine sample size.
Data exclusions
Describe any data exclusions.
No samples or animals were excluded from the analyses.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Animals arriving in our facility were randomly put into cages with five mice each. The mice were randomly assigned to experimental groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The investigators were not blinded to allocation during data collection and/or analysis.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
